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ABSTRACT OF THESIS
Scalable Feature Selection and Extraction with Applications in Kinase
Polypharmacology
In order to reduce the time associated with and the costs of drug discovery, machine
learning is being used to automate much of the work in this process. However the
size and complex nature of molecular data makes the application of machine learning
especially challenging. Much work must go into the process of engineering features
that are then used to train machine learning models, costing considerable amounts
of time and requiring the knowledge of domain experts to be most effective. The
purpose of this work is to demonstrate data driven approaches to perform the feature
selection and extraction steps in order to decrease the amount of expert knowledge
required to model interactions between proteins and drug molecules.
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1.1 Challenges in Drug Discovery
Drug Discovery is known to be an expensive and time-consuming process. On average,
it takes nearly a decade, with research and development costs exceeding $1.4 billion,
to develop a single successful candidate that is able to gain FDA approval [8, 15].
Not surprisingly, the level of investment in pharmaceutical r&d has increased in
order to deliver higher quality treatments as well as to bring down the cost of these
treatments to the consumer. However despite these increased levels of investment in
pharmaceutical r&d, the progress that has been made in achieving these goals leaves
much to be desired. In fact, the number of new FDA approved drugs has roughly
halved every 9 years since 1950 [34], suggesting that new approaches must be taken
to address this problem.
Drug Discovery is difficult for a number of reasons. For one, the number of
active, or binding, compounds are greatly outnumbered by inactive, or non-binding,
compounds. As the size of the molecular space is estimated to be between 1023 -
1060, the problem of “discovering” an active compound can be likened to finding a
needle in the haystack [29]. Secondly, many existing methods for identifying active
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binding compounds, such as molecular docking simulations, are not highly accurate
or able to reliably select active binding compounds, and restrict the throughput of a
drug discovery pipeline. Thirdly, gaining access to rich datasets is difficult as many
pharmaceutical companies do not publicly share much of the data they generate
from their own research, making progress in developing practical computational drug
discovery methods more difficult to achieve.
1.2 Improving Drug Discovery with Machine
Learning
In recent years, the availability of larger amounts of realistic data [27] as well as
advancements in machine learning and deep learning have given rise to the hope of
making substantial improvements in the throughput and efficiency in the drug discov-
ery process. The focus of this work is to demonstrate how these modern techniques
can be used in conjunction with a focus on efficiently scaling to the available com-
putational resources to address some of the aforementioned challenges. The problem
of interest in this work is the development of methods to predict the likelihood of a
drug-like molecule binding to a given target protein (figure 1.1). In Chapter 2, we
present a feature selection method that uses an ensemble of weak learners in parallel
to not only make the prediction for this task, but to also learn which features are
most informative in a data-driven manner. In Chapter 3, we present a method that
is able to learn feature representations directly from molecular structures as input,
removing the need for explicit feature extraction steps during preprocessing. Fur-
thermore, the method implements a distributed optimization procedure that again
scales to the amount of available compute power. In Chapter 4, future directions
for research are discussed that examine ways in which the molecular search space
can be traversed more efficiently to develop better drug-like molecule libraries. Two
2
overarching themes throughout this work is the development of methods that are able
to leverage the available compute resources, however large or small, with the ability
to learn without human intervention, using the available data to perform the feature
selection and extraction steps.




Data-Driven Feature Selection in
Binding Affinity Models
2.1 Introduction
Protein kinases represent a large number of proteins in our body with essential func-
tions. Because of this, any disruption in normal kinase activity may lead to a disease
state. Additionally, due to high sequence and structural identity, selectively inhibiting
a kinase is difficult. This means a drug intended to target one kinase will likely also
target multiple other kinases. If these other kinases are normally expressed and not
implicated in the given disease it could lead to toxic off-target effects. Pharmaceuti-
cal companies test drug interactions with many different kinases in the beginning of
the drug discovery process. They do this as early as possible before lots of time and
money has gone into drug development [4]. Drugs failing late in the pharmaceutical
pipeline can be very costly, driving up the cost of drugs that do make it to market
when they have to recuperate the cost for the failed drugs. It can also be fatal when
they fail during clinical trial, because animal testing does not always give a good
indication of serious side-effects [32]. Therefore, our interest in accurate computa-
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tional models to study kinases is to develop better and safer cancer therapies, using
efficient computational predictions that reduce the time and cost of bringing a drug
to market.
We propose to use machine learning techniques to increase the accuracy of com-
putational drug discovery in order to make better predictions as early as possible. We
have seen in our own work that a small number of calculated features similar to ones
used in this study can identify active compounds for a given protein with greater than
99% accuracy. These same drug features have been used in machine learning models
in combination with docking scores to rescore interactions with one candidate drug
to multiple proteins [14]. The individual components of a molecular docking scoring
function can be used as features in a machine learning model to greatly improve the
accuracy of identifying active compounds in models specific for one protein [19]. From
a different perspective, protein features have been used in machine learning models
to predict the druggability of a protein [18]. The goal of this work is to combine all
these components in one model that would vastly improve the accuracy of predicting
the effects of new proteins and classes of drugs. The specific goal of this chapter is
to present machine learning models that can accurately predict the drug interaction
for a class of functionally related proteins (kinases), an important class of proteins
for drug discovery as already stated.
2.2 Methods
Our goal is to estimate the probability that a kinase-drug pair is active (binding) or
decoy (not binding), a binary classification task. We propose to use a random forest
classification method to address this task. A key focus of our effort is in investigating
which features are most informative for this task. To support this effort, we created a
large dataset of kinase-drug pairs and computed a wide variety of different features.
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The data used in this study comes from the kinase subset of the Directory of
Useful Decoys - enhanced (DUD-e) [27]. It is important to note that the ratio of
active to decoy compounds in DUD-e is approximately 1:50.
Data Collection
• Protein Descriptors The human canonical sequences were collected for each
protein from UniProt [3]. The sequences were submitted to three different web-
servers to collect features: ExPasy [11], Porter, PaleAle 4.0 [24], and PROFEAT
Protein Feature Server [39]. These three tools were used to ensure we collect
all features used in the DrugMiner [18] project. Additional features that these
tools calculate are also collected. ExPasy calculates many features, such as
the length, weight, half-life, isoelectric point, extinction coefficient assuming
all pairs of Cys residues form cysteines, extinction coefficient assuming all Cys
residues are reduced, instability index, aliphatic index, Grand average of hy-
dropathicity (GRAVY), and the frequency of single amino acids, amino acid
types (tiny, small, aliphatic, nonpolar, aromatic, polar, charged, basic, acidic,
hydrophobic, hydrophilic, positive, and negative), and atom types. Porter cal-
culates the predicted secondary structure based on the amino acid sequence and
classifies each amino acid as helical, beta strand, or coil. PaleAle calculates the
predicted relative solvent accessibility based on the amino acid sequence and
classifies each amino acid as completely buried (0-4% exposed), partly buried (4-
25% exposed), partly exposed (25-50% exposed), or completely exposed (50+%
exposed). PROFEAT calculates features using many different tools including
features based on the dipeptide composition of the protein sequence.
• Pocket Descriptors Inner point features are collected using PRANK [20],
software used to predict and rank binding sites. PRANK first calculates feature
vectors for heavy solvent exposed atoms (AFVs), including residue and atomic
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level features. Then feature vectors are calculated for inner pocket points (IFVs)
by summing all AFVs within an 8 A˚ radius using a distance weight function and
then appending features specific to the inner pocket point, such as the number
of H-bond donors and acceptors in its local neighborhood. The IFV from the
inner pocket point with the closest distance to the center of the docking box
calculated for molecular docking is used.
• Drug Descriptors Drug features are calculated using the Dragon Software
[36]. Dragon can calculate over 5 thousand molecular descriptors, including
the simplest atom types, functional groups and fragment counts, topological
and geometrical descriptors, and three-dimensional descriptors. It also includes
several property estimations like logP and drug-like alerts like Lipinski’s alert.
In this study 3-dimensional descriptors are left out because the input structures
for Dragon are the predocking structures and not those predicted by molecular
docking.
• Binding Descriptors The receptor files from DUD-e that were optimized
for docking are used in this study. The dimension and center of the docking
boxes are calculated using a VMD [16] tcl script to draw a box around the
co-crystallized ligand included in the DUD-e dataset and it is extended by 5 A˚
in each direction. Compounds are prepared for docking using modified ADT
scripts and a wrapper script for automation. Docking was performed using
VinaMPI [10], which allows the distribution of a large number of Autodock
Vina [38] docking jobs on MPI-enabled high-performance computers. The re-
sults of the docking jobs were submitted to Autodock Vina using the “–score-
only” option to collect the individual terms calculated in the scoring function.
This includes terms for gauss1, gauss2, repulsion, hydrophobic, and hydrogen
interactions. The values for the first model and averages of each term for all
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models are kept.
Feature Selection & Classification
The only form of preprocessing we performed was eliminating features with too many
missing values. Specifically, we eliminated 21 features computed by the Dragon soft-
ware package that had more than 5% missing values. The eliminated features had
between 23.1%-99.9% missingness. There were 167 additional Dragon features that
had less than 5% missing values and we imputed these values by using the column
average. The final full dataset contains 5,410 features and 361,786 examples. After
initial preprocessing, we train a classifier for various subsets of features and perform
feature selection.
Random forests [5] are known to produce robust classifiers that are less prone to
overfitting than ordinary decision trees. For a brief review, random forests contain a
number of decision trees, a parameter that is chosen prior to training, each of which
take random samples from the training data and random subsets of features to grow
decision trees that are often limited in depth to create “weak” learners that underfit
the testing data. By combining the “weak” learners that specialize in different regions
of the feature space, random forests are able to learn complex functions that are robust
to label imbalance or overfitting, two properties that are of great importance in our
classification problem. The decision trees that make up a random forest compute
orthogonal splits in feature space that attempt to maximize separation between the
positive and negative classes minimize what is known as the GINI Impurity. From
training a random forest, one can compute feature importances by measuring the
average after-split impurity of the feature across all trees in the forest.
The feature selection method we use is similar to those used by [23] and [2] who
also apply iterative feature selection method for classification to learn important sets
of features. In our feature selection method, we input an initial set of features F for
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which we use to train a random forest classifier. The input data, after preprocessing,
is partitioned into training and testing sets using an 80/20 stratified split, with the
test set containing the same proportion of positives to negatives as the training set.
We fix several parameters of the random forest classifier by using an out-of-bag score
to protect against overfitting, balanced class weighting when computing impurities
for the forests which inversely adjust the weights according to class frequency to get
measures of the F1-score that better reflect the random forest’s performance in cor-
rectly predicting the active class, bootstrap sampling which allows training examples
to be used in the building of more than one tree, and the GINI impurity criterion for
which to compute the split quality when building the tree. We then perform model
selection by sampling from distributions of hyperparameters, shown to be as effec-
tive as exhaustive parameter grid searching by [21], for the random forest including
the number of trees to include (30-100 trees) in the forest, the minimum number of
samples required to create a leaf node (1-100 samples), and the maximum number of
features f ∈ F to sample from F for each decision tree (√|F | and log2(|F |)). Given
the distributions over hyperparameter values, we sample 100 possible settings of hy-
perparameters each iteration, evaluating the performance of each candidate model
using k-fold cross validation, with k = 3. We define the best model trained on the
feature set to be the one which maximizes the weighted F1-score on the testing data.
We then compute the mean importance, more specifically the mean decrease in im-
purity ( 1|F |), for the set of features F , and retain all features that have above mean
importance. This strategy is employed in order to remove features with near 0 im-
portance that contribute negligible information to the classification model and do not
have a significant affect on performance. After computing the set of features to keep,
F becomes the set of features identified as relevant, reducing the dimensionality of
the input data. The iteration process continues until either a maximum number of
iterations have completed or if there are no remaining features.
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Algorithm 1 Feature Selection
1: procedure Selection Forest(F )
2: while F 6= ∅ and step < max steps do
3: X, y = load data(features = features to keep)
4: Xtrain, Xtest, ytrain, ytest = train test split(X, y)
5: best forest = RandomizedGridSearch(RandomForest,
Xtrain, ytrain).best estimator
6: feature importances = best forest.importances
7: features to keep = feature importances > 1|feature importances|
8: F = features to keep
We use principal component analysis (PCA) to visualize the various feature rep-
resentations. For our purpose of visualization, we reduce the dimensionality to 2
principal components.
Test set
We used a fixed seed when creating the test set in order to make sure all models are
tested with the same data. The test and training sets are stratified by kinase, keeping
the same proportion of active and decoy compounds for each.
Table 2.1 gives the representation of each kinase in the test set. The whole dataset
‘total’ column gives the total number of active and decoy compounds for the given
kinase in the whole dataset. The whole dataset ‘ratio 0:1’ column gives the ratio of
negative to positive class for the entire given kinase’s dataset. The remaining columns
are particular to the test set. The ‘0’ column gives the number of decoys (negative
class) in the test set. The ‘1’ column gives the number of actives (positive class) in
the test set. The ‘percent 0’ column gives the percentage of the given kinase’s dataset
that is in the negative class test set. The ‘percent 1’ column gives the percentage of
the given kinase’s dataset that is in the positive class test set. The ‘total %’ column
gives the percentage of the given kinase’s dataset that is in the test set. The ‘ratio
0:1’ gives the ratio of negative to positive test cases for the given kinase in the test
set.
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Table 2.1: Representation of each kinase in the test set
whole dataset test dataset
kinase total ratio 0:1 0 1 percent 0 percent 1 total % ratio 0:1
abl1 11,180 37 2,105 60 0.188 0.005 0.194 35
akt1 16,999 39 3,298 73 0.194 0.004 0.198 45
akt2 7,142 37 1,462 34 0.205 0.005 0.209 43
braf 10,349 40 2,036 46 0.197 0.004 0.201 44
cdk2 29,126 35 5,604 158 0.192 0.005 0.198 35
csf1r 12,720 43 2,563 54 0.201 0.004 0.206 47
egfr 36,274 43 6,936 158 0.191 0.004 0.196 44
fak1 5,516 47 1,085 14 0.197 0.003 0.199 78
fgfr1 736 2 183 116 0.249 0.158 0.406 2
igf1r 9,633 42 1,958 42 0.203 0.004 0.208 47
jak2 6,743 43 1,343 32 0.199 0.005 0.204 42
kit 10,861 42 2,144 52 0.197 0.005 0.202 41
kpcb 9,092 36 1,732 42 0.190 0.005 0.195 41
lck 28,539 41 5,569 136 0.195 0.005 0.200 41
mapk2 6,450 30 1,240 40 0.192 0.006 0.198 31
met 11,677 47 2,278 47 0.195 0.004 0.199 48
mk01 4,767 33 889 31 0.186 0.007 0.193 29
mk10 6,900 36 1,358 50 0.197 0.007 0.204 27
mk14 37,347 40 7,265 184 0.195 0.005 0.199 39
mp2k1 8,483 34 1,693 41 0.200 0.005 0.204 41
plk1 7,034 44 1,402 32 0.199 0.005 0.204 44
rock1 6,580 31 1,306 41 0.198 0.006 0.205 32
src 35,790 42 6,980 167 0.195 0.005 0.200 42
tgfr1 8,958 31 1,704 63 0.190 0.007 0.197 27
vgfr2 25,900 41 5,119 123 0.198 0.005 0.202 42
wee1 6,371 46 1,245 25 0.195 0.004 0.199 50
Evaluation
In this study, we compare the performance of machine learning models using different
feature sets and also compare the performance to the computed docking score. Dock-
ing scores are typically used for ranking compounds from most likely to least likely
to bind and there is no standard that defines an exact docking score that determines
a binding prediction. In order to compare binding predictions from the docking score
alone to the machine learning models, the maximum Youden’s index (or J value) is
calculated for each model. The best J value is calculated from the docking score
receiver operator characteristic (ROC) curve and used as a cut-off to define true pos-
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itive (TP), true negative (TN), false positive (FP), and false negative (FN) values for
the docking results. The different feature sets are described below and we compare
6 models using the feature sets given in Table 2.2. All the metric presented in the
Results are defined in Table 2.3.
Table 2.2: Evaluation Models
Model Feature Set Model Feature Set Model Feature Set
1 FS1 3 FS1 + FS3 5 FS1 + FS2 + FS3 + FS4
2 FS4 4 FS1 + FS3 + FS4 6 all features
Table 2.3: Metrics used in this study
Name Definition Formula
Youden’s index
Performance of dichotomous test. The value 1






F1 Harmonic mean of precision and recall 2TP
2TP+FP+FN
Precision Positive predictive value TP
TP+FP
Recall True positive rate TP
TP+FN
Table 2.4: Youden’s Index.
Kinase Youden’s Index Best docking score Kinase Youden’s Index Best docking score
abl1 0.35 -9.1 lck 0.29 -8.9
akt1 0.02 -8 mapk2 0.45 -8
akt2 0.22 -8.5 met 0.51 -8.9
braf 0.53 -9.6 mk01 0.6 -9.1
cdk2 0.33 -8.2 mk10 0.4 -8.7
csf1r 0.23 -8.9 mk14 0.28 -8.5
egfr 0.15 -8.7 mp2k1 0.13 -7.8
fak1 0.52 -8.4 plk1 0.2 -8.6
fgfr1 0.01 -8 rock1 0.4 -7.7
igf1r 0.46 -8.4 src 0.17 -8.1
jak2 0.37 -9.3 tgfr1 0.56 -9.6
kit 0.24 -8.5 vgfr2 0.36 -9
kpcb 0.33 -8.5 wee1 0.76 -10
Overall 0.23 -8.6
• Feature Set 1 (FS1): This set is selected using the entire dataset and using
the active or decoy binary labels. This is to collect the most important features
for making the classification in which we are interested (i.e. active vs decoy).
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• Feature Set 2 (FS2): This set is selected using only protein and pocket
features and using the kinase as a label. We do this to ensure we have protein
features to test whether or not they help identify which kinase compounds bind
to and not just identify kinase inhibitors in general.
• Feature Set 3 (FS3): This set is selected using the drug features with the
kinase as a label. This is also used to help with kinase selectivity.
• Feature Set 4 (FS4): This set contains all docking features, which includes
terms for gauss1, gauss2, repulsion, hydrophobic, and hydrogen interactions for
the first docked model produced using molecular docking and an average over
all models (the default value of 9 models was kept when running Vina). There
is also a feature for the final docking score.
2.3 Results
Youden’s Index for Docking Scores
The maximum Youden’s index (or J value) is calculated and used to define TP, FP,
TN, and FN values using docking scores. The best J values and docking score cut-off
for each kinase and on the dataset overall all are given in Table 2.4.
PCA of Feature Sets
We performed a PCA of each Feature Set (FS) described in the Methods section.
Figures 2.1 and 2.2 plot the first two components for FS1-FS4. FS1 contains 776
features all which are drug features. FS2 contains three protein features that are
most important in determining the kinase. These are [G3.1.1.1.19], [G4.1.23.3],
[G4.3.17.2] and come from the PROFEAT webserver [39]. These correspond to an
autocorrelation descriptors based on the distribution of amino acid types along the
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(a) Feature Set 1 (b) Feature Set 4
Figure 2.1: PCA of FS1 and FS4
(a) Feature Set 2 (b) Feature Set 3
Figure 2.2: PCA of FS2 and FS3
protein sequence, a protein-ligand binding site propensity descriptor, and a protein-
DNA interface propensity descriptor, respectively. FS3 gives us 191 features which
has an overlap of 134 features with FS1, so this set has 57 new features in it. FS4
has 11 features.
Evaluation of Models Containing Different Feature Sets
Metrics (which are defined in Table 2.3) for each model are given in Table 2.5 and
a comparison to the docking metrics obtained using the test set is also given. All
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models do very well at identifying the decoy compounds or negative class. However,
given the ratio of decoys to actives, a model could always predict decoy and give good
results. Therefore, our focus is on the positive class metrics. Interestingly Model 2
which is all docking features and would hopefully be highly predictive, has the worst
performance in all metrics. Model 2 still performs better than docking alone by F1-
score. Model 5 gives the best F1-score which is a key metric as it is a balance between
the precision and recall. It also gives the best recall of 0.92. Additionally, this is the
model that includes protein features and we are interested in the added benefit of
including them.
In Table 2.6 we further analyze the per kinase performance. All metrics here are
using Model 5 and again the metrics based on docking scores alone are also given.
The “Per kinase” columns are metrics on each individual kinase from the analysis
given in Table 2.5. The “Leave-one-out” columns are additional models using the
same feature sets as Model 5, but in which one kinase is left out for testing while all
the other kinases are in the training set.
2.4 Discussion
We can see from the PCA (figures 2.1, 2.2) that FS1 (drug features selected based
on active or decoy classification) has a fairly good separation of the two classes and
alone gives good predictions with an F1-score of 0.87. FS4 (docking features) has
some separation between the classes but also a sizable overlap and only an F1-score
of 0.28 (Model 2) for classifying the compounds. FS3 (drug features selected based on
kinase classification) do not do a great job at kinase classification and do not improve
the model over using just FS1 (Model 3 vs Model 1). Only three protein features
were selected for their ability to classify the kinase (FS2) and this model, Model 5,
gives the best F1 score.
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Even though the drug features are by far the most informative features in these
models, they cannot account for kinase selectivity. When including features that are
informative at classifying the kinase, we had a slight increase in F1 score. Even though
kinase inhibitors are promiscuous and kinases have a high sequence and structural
similarity, this provides hope that protein features can be informative in universal
(multi-protein) models for drug binding.
We can see that the per kinase performance is much better when each kinase
is represented in the training set by comparing the “Per kinase” and “Leave-one-
out” columns in Table 2.6. However, many kinases still perform very well in the
“leave-one-out” analysis. We believe that as we add more kinases to the model the
“leave-one-out” analysis will improve. Recent results using a diverse set of proteins
also show promise to improve models.
To exemplify the usefulness of our method, we have identified a compound that
would never be identified in a docking virtual screen as an active compound (re-
ceiving a score of +95.19, when the most negative scores predict binding), that has
been saved using this machine learning model. An example of such a compound
is CHEMBL448926, an ackt1 active compound. This compound is an actual ackt1
inhibitor patented by Merck and Co Inc. (Patent ID US7544677) and directed to
chemotherapeutic compositions. The reason this compound may be lost during dock-
ing is it a potent allosteric inhibitor [35].
Docking is often used as a tool to enrich a subset of data and therefore early
enrichment is a common important metric. For example, if a large virtual drug set
has 2% unknown active compounds in it then hopefully the top subset of scored drugs
by docking will have maybe 10% active compounds in it. This would allow researchers
to select a smaller set of drugs for experimental testing and have a greater success
rate than randomly selecting a subset for testing. We can see here that the precision
is always low for docking, therefore to recover the same amount of active compounds
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using docking you would always have a much higher false positive rate making the
number of compounds needed for experimental validation to be much higher for the
same success rate.
With the test case presented here evaluated with Model 5, which includes protein
features and gives the best F1 score, 97% of the test data is classified as non-binding.
Therefore, 97% of the data can immediately be discarded and you would lose less
than 10% of the binding compounds at this prediction stage. Experimentally testing
the predicted active compounds would give an 83% success rate at identifying active
compounds. Testing the same number of compounds based on docking score alone
would have less than a 27% success rate. Part of the problem here is that docking
scores are not a good indicator of binding when looking at multiple proteins. The
range of docking scores varies per protein. This demonstrates a huge advantage to
our machine learning approach for a multi-protein model.
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Table 2.5: Comparison of performance for both classes on the testing set.
Model Class Precision Recall F1-Score Class Precision Recall F1-Score
1 0 1.00 1.00 1.00 1 0.83 0.92 0.87
2 0 0.98 0.98 0.98 1 0.26 0.30 0.28
3 0 1.00 1.00 1.00 1 0.83 0.92 0.87
4 0 1.00 1.00 1.00 1 0.83 0.91 0.87
5 0 1.00 1.00 1.00 1 0.84 0.92 0.88
6 0 1.00 1.00 1.00 1 0.85 0.89 0.87
Docking 0 0.99 0.58 0.73 1 0.04 0.67 0.07
Table 2.6: Evaluation metrics per kinase for the positive class
Per Kinase Leave-one-out Docking
Kinase Prec. Recall F1 Prec. Recall F1 Prec. Recall F1
abl1 0.92 0.95 0.93 0.86 0.95 0.9 0.06 0.72 0.11
akt1 0.86 0.96 0.91 0.84 0.81 0.82 0.03 0.29 0.05
akt2 0.94 0.94 0.94 0.83 0.8 0.81 0.04 0.59 0.07
braf 0.85 0.98 0.91 0.76 0.85 0.8 0.06 0.80 0.11
cdk2 0.85 0.77 0.81 0.6 0.31 0.41 0.04 0.78 0.08
csf1r 0.82 0.83 0.83 0.62 0.59 0.6 0.03 0.63 0.06
egfr 0.85 0.91 0.88 0.76 0.75 0.75 0.03 0.81 0.05
fak1 0.75 0.86 0.8 0.8 0.77 0.78 0.03 0.86 0.06
igf1r 0.93 1.00 0.97 0.9 0.92 0.91 0.05 0.86 0.09
jak2 0.97 0.94 0.95 0.87 0.77 0.82 0.06 0.5 0.10
kit 0.83 0.92 0.87 0.74 0.88 0.81 0.05 0.58 0.08
kpcb 0.70 0.93 0.80 0.45 0.32 0.37 0.04 0.86 0.08
lck 0.94 0.93 0.94 0.8 0.83 0.82 0.05 0.49 0.09
mapk2 0.93 0.97 0.95 0.72 0.37 0.49 0.06 0.65 0.10
met 0.87 0.96 0.91 0.75 0.77 0.76 0.05 0.81 0.09
mk01 0.91 0.97 0.94 0.78 0.69 0.73 0.16 0.71 0.26
mk10 0.88 0.86 0.87 0.67 0.51 0.58 0.06 0.82 0.11
mk14 0.90 0.85 0.88 0.76 0.5 0.6 0.05 0.56 0.09
mp2k1 0.80 0.95 0.87 0.59 0.48 0.53 0.03 0.93 0.05
plk1 0.82 0.84 0.83 0.73 0.5 0.59 0.03 0.91 0.06
rock1 0.88 0.85 0.86 0.63 0.32 0.42 0.05 0.88 0.10
src 0.93 0.97 0.95 0.86 0.87 0.86 0.03 0.88 0.06
tgfr1 0.94 0.98 0.96 0.89 0.83 0.86 0.09 0.84 0.17
vgfr2 0.93 0.90 0.92 0.8 0.79 0.8 0.05 0.65 0.10
wee1 0.93 1.00 0.96 0.75 0.58 0.65 0.14 0.8 0.24
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Limitations
While our results highlight the potential of our approach, there are several limitations
of our evaluation that warrant further investigation. The main limitation is that we do
not know whether a compound that is active for one kinase is not active for another.
There is some overlap between the 26 different active sets but it is not much. Since
selectively inhibiting a kinase is difficult it should be experimentally validated before
marking a compound that is active for one kinase as not for another one. It is also
difficult to tell if a given active for one kinase is in the decoy set for another kinase
because the active and decoy compounds in DUD-e come from different databases,
CHEMBL [12] and ZINC [17], respectively. Having an all-to-all set of connections
where we know whether every drug in our dataset binds or does not bind to every
protein in our dataset may uncover important features for this selectivity. Also, due
to concerns with the fgfr1 dataset (i.e. the proportion of actives to decoys does not
match what is expected from DUD-e), we have excluded fgfr1 compounds from our
test set.
Future Work
Some potential future directions include (1) evaluating different ways of using the
pocket features that may correlate better with predictions, (2) incorporating infor-
mation on multiple possible binding sites in the model, and (3) incorporating diverse
proteins in the dataset.
2.5 Conclusion
We successfully created a model of several kinases that makes good binding predic-
tions. We found that the features we collected greatly increased binding predictions
when used in a machine learning model over docking scores alone. A model using
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features selected based on which kinase they belong to gave the best F1 score which
balances precision and recall. We calculate a nearly 60% increase in success rate for
discovering active compounds over docking.
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Chapter 3
Distributed Learning of Molecular
Feature Representations
3.1 Introduction
It is common for modern screening pipeline methods in computational drug discovery
to require the use of feature extraction steps to compute meaningful vector represen-
tations of drug molecules that can later be used as inputs in predictive models for
protein-drug interactions. This may be undesirable in at least two ways. First, these
features are gathered independently of the end task, meaning that they are not able
to be directly optimized for the task of interest in a manner that understands the
relationships between the available data and the task of interest. Secondly, these
extraction methods require some degree of domain expertise in determining which
features are appropriate for the task and further, which parameters should be used
to compute these features.
In this chapter we demonstrate how a deep learning methodology can be used to
learn feature representations of drug-like molecules in a data-driven manner that can
alleviate much of the burden in the data preparation. We show how the learned fea-
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ture representations are able to provide accurate predictions of molecular properties
for the drug molecules in our dataset as well as discriminate between protein-kinase
inhibitors.
3.2 Related Work
One commonly used method for representing molecular structures is by encoding
them using the smiles (simplified molecular-input line-entry system) format. A smiles
string encodes the atoms and bonds, as well as the types of the bonds, of a molecule.
A given smiles representation uniquely identifies a molecule, and for a given molecule
their may exist a number of valid permutations of these unique identifiers. As this
format is a string representation of a molecule, it is necessary to compute a vector
representation of a molecules smiles representation for use as input to a machine
learning system.
Drug molecules can also be understood as graph structured data. Each node in
the molecular graph G represents an atom, and each edge euv ∈ G can be thought of
as a bond between two atoms u and v, with the edge euv labeled by the type of bond
between the atoms u, v. Leveraging this graph representation Gm of a molecule m,
one can extract a vector representation describing Gm in some context.
We briefly review some applications in which these representations have been used
in machine learning, highlighting some of their limitations and thus motivating the
need for data driven modeling to be used in practice.
Molecular Descriptors
Molecular descriptors are the output of some computational process “which trans-
forms chemical information encoded within a symbolic representation of a molecule
into a useful number. . . ” [37]. Several solutions exist for the calculation of molecular
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descriptors that can be used as input to machine learning models for tasks to predict
molecular properties and activities [6, 26, 36]. A popular option is the Dragon soft-
ware suite which is able to calculate 5,270 unique molecular descriptors that include
features such as simplest atom types, functional groups and fragment counts, topolog-
ical and geometrical descriptors, three-dimensional descriptors, as well as estimates of
various properties relevant to computational drug discovery such as solubility (logP)
and drug-like indices. Determining which of these features may be appropriate for a
task either requires domain expertise, trial and error, or the simplest solution in using
all of the available features and using some feature selection process to filter out those
that are less informative according to some threshold. While using a feature selec-
tion process does help to remove the burden of domain expertise, a disadvantage to
this approach is that unnecessary dimensionality may be introduced, restricting the
possible approaches one may use to learn a task in a timely manner as a consequence
of the curse of dimensionality.
Numerous studies have been performed in the context of drug-protein binding
interactions that have made use of molecular descriptors as feature representations of
molecules [7, 14, 18, 19, 22, 30]. In addition to traditional machine learning methods,
Deep Neural Networks (DNNs) trained on molecular descriptors as feature represen-
tations have been successfully applied to problems in drug discovery. In the work by
[7], Multi-Task (DNNs) were successfully applied to predict the targets of multiple
PubChem assays using 3764 molecular descriptors gathered from the Dragon soft-
ware suite. The authors compared their methods to several benchmarking methods,
including a single-task DNN, and show that in the majority of cases their method
exceeds the baseline performance in terms of the pearson correlation coefficient (i.e.
R2). In further work on applying DNNs to drug discovery, a competition launched
by Merck & Co. on the Kaggle data science platform was used to generate fur-
ther interest in applying modern machine learning techniques to the prediction of
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molecular properties relevant to drug discovery. The data provided in the Merck &
Co. molecular activity challenge consisted of molecular descriptors along with a set
of activities as labels for each distinct molecule. The winning team subsequently
published their results with the assistance of Merck & Co. in which they detail a
crucial component behind their successful ensemble learning method, a DNN [22],
showing that the DNN in most cases is able to outperform the RF across a number
of hyperparameter settings on each of 15 selected datasets. While the results of early
applications of DNNs were impressive in their own right given the time context, the
use of molecular descriptors imposes a prior belief that all relevant or task-specific
information is contained within these sets of descriptors, an obvious limitation that
should be addressed in future methodologies.
Molecular Fingerprinting
Rather than explicitly computing features for a molecule such as a drug-like prop-
erty or index, it is possible to instead compute a vector representation that identifies
the molecule in a vector space with some intrinsic meaning. Algorithms for do-
ing this calculation are known as molecular fingerprinting methods. Examples of
these include morgan fingerprints [25] and extended connectivity circular fingerprints
(ECFP) [33]. These algorithms compute a unique binary valued vector that identifies
a given molecule based upon the atoms that it contains and their features. The state
of the art fingerprinting algorithm, ECFP, computes a representation that can be used
to understand properties such as similarity between molecules which can be helpful
in predicting specific properties of a possibly unknown molecule as well as possible
identification of active binding molecules to a target protein. However, in terms of
extracting a representation for a machine learning task, a limitation of these methods
is that they are computed independently of the task of interest, potentially limiting
the performance of machine learning models trained using these representations.
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Neural Fingerprinting
Recently, a deep learning “neural” fingerprinting method was proposed in the work
by [9]. The authors alter the ECFP algorithm by introducing a differentiable function
to compute molecular fingerprints, allowing the method to be optimized for specific
tasks, an advantage over previous methods. Subsequently, a number of variations
of this type of network using graph convolutions have been introduced by various
groups. The work by [13] summarizes each of these techniques, and provides a unified
definition of these methods named Message-Passing Neural Networks, or MPNNs,















where Mt is a specified message passing function, Ut is a specified update func-
tion, htv is the hidden state and m
t
v is the message received by node v at time t.
This step is computed for all nodes v ∈ G and is repeated for each node a spec-
ified number of iterations given as T . The result is the flow of local information
from each node v ∈ G across the molecular graph.
• Readout Phase
yˆ = R({hTv | v ∈ G}) (3.3)
where R is a specified “readout” function of the hidden node states at the end
of message passing at time T and yˆ is the predicted target value of the network.
MPNNs are powerful in that they are able to learn on graphs that vary in topol-
ogy, making them flexible for applications in which the inputs express this variety.
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While the hidden states htv can be updated simultaneously for all nodes in a graph
Gm at time t, the message passing phases are sequential operations in that h
t+1
v is
not able to be computed until the previous value htv is known, so one must iterate T
times to complete the message passing. When learning on large amounts of training
data, this may become a troublesome property and so we explore a distributed opti-
mization algorithm, HOGWILD! [31], as a possible method to address this concern
in a practical application.
3.3 Methods
Dataset
The dataset used in the subsequent experiments is derived from the Directory of Use-
ful Decoys-Extended (i.e. DUD-E), a molecular docking database. The molecules in
this study are identified as active or decoy binding for the kinase subset of DUD-E
and we use their smiles representations during preprocessing. From the smiles rep-
resentations, the deepchem python library is used to construct the molecular graphs
using the atom and bond feature extraction code, which encode various properties of
the atoms in a given molecule as well as the bond types [1]. The atom features are
used as the initial value of ht=0v of size 70 and the bond features are used as the value
of evw of size 6. The dataset was split into 3 partitions that are consistent across each
experiment. The training and testing sets were generated using an 80/20 stratified
split that keeps the number of positives consistent across each set. The training set
was then further divided into a training and hold-out validation set using a 90/10
split, again using a similar stratified scheme, keeping the proportion of positives con-
sistent across each split. In total there are 361,045 examples in the dataset, 259,952
of these in the training split, 28,884 in the validation split, and 72,209 in the testing
split.
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Table 3.1: Description of dataset partitioning





Our implementation specifies the message passing phase as the result of two functions
Mt and Ut, which compute the updated message vector m
t+1
v and the update hidden
state vector ht+1v . m
t+1





w, evw) = h
t
v ‖ htw ‖ evw (3.4)





v ) = ReLU(m
t+1
v ) (3.5)
where ReLU(x) = max(0, x). Finally, we specify the readout function R as:
R({hTv | v ∈ G}) =
∑
v∈G
ReLU(hTv ‖ hTv ) (3.6)
using consistent definitions for the ReLU non-linearity and concatenation. In the case
of classification, the output of the network yˆ is defined as:
yˆ = softmax(O(R({hTv | v ∈ G}))) (3.7)
and in the case of regression we define the output yˆ as:
yˆ = O(R({hTv | v ∈ G})) (3.8)
where O is a linear transformation. We explore a number of configurations for the
network parameters, using a randomized hyperparameter search to efficiently explore
the hypothesis space. All code implemented using the PyTorch deep learning frame-
work and deepchem molecular machine learning library [28], [1].
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Network Training
To reduce the time for the MPNN to fit our dataset, we use the HOGWILD! dis-
tributed stochastic gradient descent (SGD) optimization algorithm [31]. HOGWILD!
is an asynchronous implementation of SGD that trains a model in a distributed fash-
ion by using multiple processes to update the parameters of a single shared copy
of the model. The updates are lock-free, in that the processes are free to update
the shared copy after computing the gradient for their respective batches and that
there is no central authority that must approve of the updates. This alleviates issues
that may come with a synchronous algorithm, whose overall computation time per
mini-batch would depend on the computation time of the slowest worker. While it is
possible that the processes overwrite each others work during the training of the net-
work, it has been shown under the assumption that updates to the shared parameters
are sparse, that one can achieve a near linear increase in convergence. We provide a
visualization of this optimization algorithm in 3.1.
To give an overview of the HOGWILD! implementation, we initialize n training
processes where each process gets a copy of the data, a reference to the shared memory
model, and a unique random seed. Then each process begins its own SGD, treating
the shared memory parameters as their own. The processes make updates and get
the new values of the model parameters asynchronously. Thus after the initial copy,
it is possible that the individual training processes are operating with different, but
related, copies of the model parameters, introducing noise to the network training
which can be understood as a form of regularization.
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Figure 3.1: Visualization of the Hogwild! training algorithm
3.4 Results
Experiment 1: Predicting Molecular Properties
We first evaluate our method by predicting molecular properties that have been com-
puted by the Dragon software suite [36]. The goal of this experiment was to under-
stand how well the method could learn these properties in order to determine whether
more complicated tasks would even be possible. To evaluate these results, we use the
pearson correlation coefficient, or R2 metric, which measures how well a predictive
model’s output correlates to the true target output.
Each network was trained for a separate task using a single training process with
batch size of 300, using the ADAM optimizer with learning rate of 1e − 3, readout
function R which takes as input a vector of size 128 and computes an output vector of
size 140, and output layer O which takes as input a vector of size 128 and computes
an output scalar. The target values for each task were standardized using the mean
and standard deviation of the given feature column in the training set. The results
on each of the separate task are measured given in figure 3.2.
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Figure 3.2: R2 values for molecular property predictions on testing set
Experiment 2: Classification of Kinase Inhibitors
This task attempts to determine whether or not a given drug molecule inhibits a
protein kinase target, a binary classification task. This classification is similar to
what was done in the previous chapter where we use only drug features in our model
1 to identify the kinase inhibitors. We evaluate the performance of this classification
using the precision, recall, and f1-score for each class to understand how well the
model is able to correctly predict the active compounds in our dataset.
We use a random hyperparameter search to choose the number of training pro-
cesses, the size of the output vector computed by readout function R, the size of
the input vector for the output layer O, the number of message passing steps T , the
batch size, and learning rate to use for training. We sample 100 configurations based
upon this, then evaluate each model (for each separate training process) on the test
set, choosing the model that gives the best f1-score on the testing set from which we
30
choose the optimal set of hyperparameters. From this, we then train 5 models with
the optimal hyperparameter settings and vary the number of training processes. We
then evaluate each of these on our testing set and report the mean metrics (over all
training processes) in table 3.2.
Table 3.2: Comparison of kinase inhibitor classification between the MPNN method
and Model 1 from the feature selection method.
n processors Class Prec. Recall F1-score Class Prec. Recall F1
1 0 0.99 1.00 1.00 1 0.93 0.68 0.79
2 0 1.00 1.00 1.00 1 0.88 0.88 0.88
3 0 0.99 1.00 1.00 1 0.92 0.78 0.84
4 0 1.00 1.00 1.00 1 0.90 0.84 0.87
5 0 1.00 1.00 1.00 1 0.91 0.85 0.88
Model 1 0 1.00 1.00 1.00 1 0.83 0.92 0.87
Figure 3.3: Mean precision score on validation for each number of training processes,
per epoch
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Figure 3.4: Mean recall score on validation set for each number of training processes,
per epoch
Figure 3.5: Mean f1-score on validation set for each number of training processes, per
epoch
3.5 Discussion
Our results show that the MPNN model can be used to classify the kinase inhibitors
with performance on par with our previous method that uses pre-computed features.
It can also be observed that the use of at least 2 training processes appears to result
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in a significant improvement in recall and f1 scores on the test set. This improvement
is also achieved earlier in the network training, as seen in figures 3.3, 3.4, and 3.5.
However, it does appear that beyond the use of 2 training processes, the improvements
are not as substantial. This may be related to the number of model parameters and
the sparsity of the updates from each of the training processes.
Copyright c© Derek Jones, 2018.
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Chapter 4
Conclusions and Future Directions
In this thesis, we have presented two approaches for the modeling of interactions
between drug-like molecules and protein kinase targets. Both of these approaches
prioritize the task of extracting information directly from the available data rather
than relying on expert knowledge. Additionally, these approaches are distributed in
nature, allowing them to scale to the available resources, however large or small those
may be. Most importantly, we have shown that these approaches are robust to the
class imbalance within our dataset, giving confidence that these algorithms would be
successful in identifying active compounds which could potentially lead to adverse
reactions.
Future directions for research include the modeling of more complex tasks such
as the binding affinities between the protein targets and drug molecules. In addi-
tion to this, it would also be interesting to learn multi-output models that quantify
the uncertainty associated with each prediction, especially interesting in the case of
regression models. Further work with larger datasets and distributed optimization
algorithms would be another worthwhile direction to pursue.
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